Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Perspective
Nature Reviews Cancer 4, 979–987 (1 December 2004) | doi:10.1038/nrc1506
Gefitinib |[mdash]| a novel targeted approach to treating cancer
&
Abstract
Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment of patients with advanced non-small-cell lung cancer in many countries. Studies have indicated its potential for treating patients with other types of solid tumours. Investigation of gefitinib has not only increased our knowledge about the biology of EGFR signalling, but is contributing to our evolving understanding of which tumours are EGFR dependent.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
